Medtronic Spinal Fusion Device Faces U.S. FDA Review

Medtronic Inc.’s experimental spinal fusion device Amplify didn’t work as well after five years as it did in two-year tests previously reported by the company, according to U.S. regulators weighing its approval for sale.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.